You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍造好 再鼎醫藥及藥明巨諾漲8%至17% 惟三葉草回吐6%
恆指今日(8日)高低見17,753/17,588,現報17,655,反覆續跌14點,總成交額498億元。 醫藥股今天普遍造好跑贏,尤其是藥明巨諾-B(02126.HK)四連升,最高見2.98元創逾三個月高,現報2.9元,續升近17%。 再鼎醫藥(09688.HK)首三季營收按年升31.8%至2.01億美元,虧損按年收窄逾37%至2.39億美元。該股今日曾急漲10.9%至24.4元,創逾三個月高,現報23.85元,回升8.4%。 藍籌藥明生物(02269.HK)繼昨天回吐守穩250天線後,今天高見52.45元,現報51.35元,回升4.5%。 藍籌翰森(03692.HK)、國藥控股(01099.HK)、石藥(01093.HK)、中生製藥(01177.HK)、以及非藍籌康龍化成(03759.HK)、康希諾(06185.HK)、百濟神州(06160.HK)、君實生物(01877.HK)升幅則介乎約2%至4%不等。 百心安-B(02185.HK)升9.8%報3.6元。微泰醫療-B(02235.HK)續升3%報4.43元。 然而,三葉草生物-B(02197.HK)反覆回吐6%報0.79元,股價重失50天線(0.81元)。四環醫藥(00460.HK)續跌近1.5%報0.68元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account